Eyenovia CEO, CMO and Chairman Dr. Sean Ianchulev to Present at Eyecelerator @ American Society of Cataract and Refractive Surgery (ASCRS) 2022
April 20, 2022 08:00 ET
|
Eyenovia, Inc.
NEW YORK, April 20, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP™) investigational...
Eyenovia Announces Poster Presentation at the 2022 American Society of Cataract and Refractive Surgery Annual Meeting
April 19, 2022 08:00 ET
|
Eyenovia, Inc.
NEW YORK, April 19, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP™) therapeutics, today...
Eyenovia Reports Fourth Quarter and Full Year 2021 Financial Results
March 28, 2022 16:05 ET
|
Eyenovia, Inc.
Successfully completed Type A meeting with FDA and anticipates MydCombi™ NDA resubmission in Q3 2022 Enrolled first patient in the Phase 3 VISION-2 study evaluating MicroLine as an on-demand...
Eyenovia to Report Fourth Quarter and Full Year 2021 Results on Monday, March 28
March 21, 2022 08:00 ET
|
Eyenovia, Inc.
NEW YORK, March 21, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP™) therapeutics,...
Eyenovia Announces Positive Study Results Demonstrating that its Optejet® Delivery Technology Reduces Conjunctival Cell Toxicity from Preserved Ophthalmic Solutions to a Level Comparable with Non-Preserved Solutions
March 15, 2022 08:00 ET
|
Eyenovia, Inc.
NEW YORK, March 15, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP™) therapeutics, today...
Eyenovia Strengthens Balance Sheet with a $15 Million Institutional Capital Investment from Armistice Capital Master Fund Ltd.
March 04, 2022 07:00 ET
|
Eyenovia, Inc.
NEW YORK, March 04, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP™) therapeutics, today...
Eyenovia Concludes Type A Meeting with FDA Related to MydCombi™ NDA Resubmission
February 08, 2022 08:00 ET
|
Eyenovia, Inc.
NEW YORK, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP™) therapeutics, today...
Eyenovia Announces Changes to Board of Directors
February 07, 2022 08:30 ET
|
Eyenovia, Inc.
NEW YORK, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP™) therapeutics, today...
Eyenovia Reports Third Quarter 2021 Financial Results
November 10, 2021 16:05 ET
|
Eyenovia, Inc.
On track with VISION-2 phase 3 presbyopia trial and expedited resubmission of MydCombi™ New Drug Application as a drug/device combination in early 2022 Current cash resources anticipated to be...
Eyenovia to Participate in Myopia Panel Discussion at the Eyecelerator@AAO 2021 Meeting
November 08, 2021 08:00 ET
|
Eyenovia, Inc.
NEW YORK, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array...